🚨 Medical cannabis is becoming increasingly common in the UK workplace. Are employers ready?

Since 2024, the number of prescriptions for medical cannabis in the UK has continued to attract attention.

Recent NHS Business Services Authority data indicates that private medical cannabis prescriptions more than doubled between 2023 and 2024.

So what does this mean for workplace health & safety?

Medical cannabis is considered a legitimate, legally prescribed medicine. It should not automatically be treated in the same way as illicit or recreational cannabis.

But that doesn’t mean there are no safety considerations.

Depending on the individual, the product, dosage & timing, cannabis-based medicines can potentially cause effects such as:

🔹 Drowsiness
🔹 Reduced concentration
🔹 Slower reaction times
🔹 Dizziness
🔹 Changes in coordination
🔹 Cognitive effects

And in safety-critical roles, even a temporary impairment could have serious consequences.

The UK Government is clear that it remains illegal to drive when impaired by a prescribed drug — including cannabis. There is a statutory medical defence in certain circumstances for prescribed medicines, but there is no defence where a person’s driving is actually impaired.

This creates an important challenge for employers.

A positive cannabis test doesn’t necessarily answer the safety question.

It may tell us that THC or its metabolites are present — but it doesn’t necessarily tell us when the cannabis was consumed, whether it was prescribed, or whether the employee is currently impaired.

That means workplace drug & alcohol policies need to evolve.

Employers should be thinking about:

✅ How prescribed cannabis is disclosed & managed
✅ Confidentiality & medical information
✅ Fitness for work
✅ Safety-critical duties
✅ Medication reviews & occupational health input
✅ How positive drug test results are interpreted
✅ The difference between drug use, prescribed treatment & impairment
✅ Supporting employees without compromising workplace safety

The CQC has also highlighted the rapid growth of private prescribing of cannabis-based medicinal products, reporting a 130% increase in dispensed items between 2022/23 and 2023/24 in England.

The conversation is therefore no longer simply:

“Does this employee use cannabis?”

It needs to become:

“Is this employee safe & fit to perform their role?”

That is a much more complex, but much more important, question.

💬 What do you think?

Are UK employers & workplace drug testing policies keeping pace with the rapid growth of prescribed medical cannabis?

Get in touch with Innovative Testing Solutions to discuss how we can help.